Ecnoglutid

Ecnoglutide mimics - like other incretin mimetics - the body's own intestinal hormone GLP-1 (Glucagon-like Peptide-1): via the GLP-1 receptor, a glucose-dependent insulin secretion, a dampened glucagon release, a slowed gastric emptying, and a reduction in appetite are described. The conceptual distinctive feature is the 'biased' signaling: in the first description (Molecular Metabolism 2023), ecnoglutide is characterized as a cAMP-biased GLP-1 analogue that strongly triggers the intracellular cAMP signaling pathway while at the same time causing hardly any receptor internalization. The low receptor internalization is the measured value reported in the first description; the internalization and beta-arrestin pathway is not separately quantified in the source. This bias is discussed in the literature as a possible reason for a sustained effect and favorable metabolic effects. As documented molecular details, the following are described: a peptide with one amino acid substitution site (alanine to valine at position 8) and an attached fatty acid side chain (a C18 diacid via a linker) that extends the residence time in the body and is intended to allow once-weekly administration.

The published efficacy and tolerability data come predominantly from studies in Chinese adults with overweight/obesity or type 2 diabetes; several authors are employed by Sciwind (study sponsor and funder). The distinguishing feature compared with conventional GLP-1 agents is the cAMP-biased signaling - a principle described in studies but not yet conclusively classified in terms of its long-term clinical significance.

The compound originates from the Chinese company Sciwind Biosciences (Hangzhou) and was developed under the code XW003. The preclinical/pharmacological first description appeared in 2023 in Molecular Metabolism (cAMP-biased GLP-1 analogue). This was followed by a Phase 2 study in type 2 diabetes (145 adults, 20 weeks, HbA1c endpoint; Nature Communications, 27 Sep 2024). The Phase 3 program comprises the obesity study SLIMMER (randomized, double-blind, placebo-controlled, 36 centers in China, 664 participants, primary endpoints at week 40; principal investigator Linong Ji; registered as NCT05813795; published in The Lancet Diabetes & Endocrinology, 21 Jun 2025) as well as the diabetes program EECOH with EECOH-1 (monotherapy versus placebo, 32 centers, 24 weeks, 211 participants; Nature Communications, 7 Jan 2026) and EECOH-2 (versus dulaglutide on top of metformin, 52 hospitals, 52 weeks, non-inferiority, 623 randomized; The Lancet Diabetes & Endocrinology, October 2025). The NMPA approval for blood glucose control in type 2 diabetes was announced in late January 2026 (trade name Xianyida), and the approval for long-term weight management on 6 Mar 2026 (trade name Xianweiying). Pfizer licensed the exclusive commercialization rights for weight management in mainland China from Sciwind in February 2026 (up to USD 495 million in upfront and milestone payments; Sciwind remains the marketing authorization holder and continues research/manufacturing). In parallel, an oral tablet form (code XW004) is being developed - a Phase 1 study (Australia, NCT05184322) reported interim data in 2024; the oral development was later continued by the company Verdiva Bio (code VRB-101) in a Phase 2b study (EVOLVE-2, NCT07281937).